These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9522323)

  • 1. Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover.
    de Valk-de Roo GW; Netelenbos JC; Peters-Muller IR; Voetberg GA; van de Weijer PH; Bouman AA; Popp-Snijders C; Kenemans P
    Maturitas; 1997 Dec; 28(2):153-62. PubMed ID: 9522323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependent effects of recombinant human growth hormone on biochemical markers of bone and collagen metabolism in adult growth hormone deficiency.
    Bollerslev J; Møller J; Thomas S; Djøseland O; Christiansen JS
    Eur J Endocrinol; 1996 Dec; 135(6):666-71. PubMed ID: 9025710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy.
    Tobias JH; Clarke S; Mitchell K; Robins S; Amer H; Fraser WD
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1194-8. PubMed ID: 11238508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
    Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
    Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen replacement therapy continuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism.
    Voetberg GA; Netelenbos JC; Kenemans P; Peters-Muller ER; van de Weijer PH
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1465-9. PubMed ID: 7962344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.
    Hannon R; Blumsohn A; Naylor K; Eastell R
    J Bone Miner Res; 1998 Jul; 13(7):1124-33. PubMed ID: 9661076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three serum assays for bone collagen formation during postmenopausal estrogen-progestin therapy.
    Suvanto-Luukkonen E; Risteli L; Sundström H; Penttinen J; Kauppila A; Risteli J
    Clin Chim Acta; 1997 Oct; 266(2):105-16. PubMed ID: 9437539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of micronized progesterone on bone turnover in postmenopausal women on estrogen replacement therapy.
    Azizi G; Hansen A; Prestwood KM
    Endocr Res; 2003 May; 29(2):133-40. PubMed ID: 12856800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen.
    Hassager C; Risteli J; Risteli L; Christiansen C
    Osteoporos Int; 1994 Nov; 4(6):349-52. PubMed ID: 7696831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The usefulness of biochemical bone markers in predicting the response of hormone replacement therapy in perimenopausal cigarette smoking healthy women.
    Cubrilo-Turek M; Stavljenić-Rukavina A; Turek S; Kusec V; Duraković Z
    Coll Antropol; 1999 Jun; 23(1):195-201. PubMed ID: 10402723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.
    Lees B; Stevenson JC
    Osteoporos Int; 2001; 12(4):251-8. PubMed ID: 11420773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men.
    Gram J; Junker P; Nielsen HK; Bollerslev J
    Bone; 1998 Sep; 23(3):297-302. PubMed ID: 9737353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral 17beta-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women.
    Pornel B; Chevallier O; Netelenbos JC
    Menopause; 2002; 9(3):171-8. PubMed ID: 11973440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral 17 beta-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
    Mijatovic V; Kenemans P; Netelenbos JC; Peters-Muller ER; van Kamp GJ; Voetberg GA; van de Weijer PH; van der Mooren MJ
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3543-7. PubMed ID: 9360504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydrogesterone.
    Lippuner K; Haenggi W; Birkhaeuser MH; Casez JP; Jaeger P
    J Bone Miner Res; 1997 May; 12(5):806-12. PubMed ID: 9144347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.